Annual Report

The report describes Circio's 2024 advancement of circVec 3.0, including a reported 4x improvement in protein-expression potency versus circVec 2.0. It records no core business revenue and total operating expenses of NOK 42.5 million, while the Group raised NOK 28.7 million from shareholders. The CSR section reports 10 employees including consultants, 33% women on the Board, and no direct emissions identified.